Dermatitis, Atopic
Conditions
Brief summary
This study is being conducted to evaluate the efficacy and safety of 3 different application rates of topically applied Crisaborole ointment 2% over vehicle in adults with mild to moderate atopic dermatitis (AD). In each subject four application areas will be identified. Each subject will receive 4 treatments: the 3 different application rates of the active treatment and the vehicle. The areas will be randomly assigned to treatment with topical Crisaborole ointment 2% and vehicle, once daily, for 2 weeks, without occlusion.
Interventions
DRUGCrisaborole 2%
Crisaborole ointment 2% (application rate A, B, C) for 15 days (double blind)
DRUGPlacebo ointment
Placebo ointment (vehicle)
Sponsors
Innovaderm Research Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Intra-individual
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of active atopic dermatitis (AD) with at least 6 month history prior to screening and that has been clinically stable for 1 month. * Has four application areas of 3 cm in diameter with a TSS of ≥5 and TAA of moderate at Day 1. The application areas must not be located on the face, scalp, axillae, groin, genitals, hands, and feet. The application areas should be ≥1 cm apart.
Exclusion criteria
* Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study. * Subject has clinically infected AD. * Subject has a Fitzpatrick's Skin Phototype ≥5. * Subject is known to have immune deficiency or is immunocompromised. * Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or successfully treated localized carcinoma in situ of the cervix are not to be excluded. * Subject had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study. * Subject has any clinically significant medical condition that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results. * Subject has a known history of chronic infectious disease (eg, hepatitis B, hepatitis C, or infection with human immunodeficiency virus). * Subject with a known lack of efficacy to crisaborole. * Subject has a known or suspected allergy to crisaborole, including any non-medicinal ingredient, or component of the container. * Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Signs Score (TSS) | Baseline, Day 15 | Change from baseline in TSS in target lesions treated with crisaborole ointment 2% or vehicle at Day 15. Total Signs Score (TSS) of the lesion is the assessment of the severity of erythema, edema/papulation, excoriation, and lichenification. Each of these subscales is scored independently using the 4-point severity scale with a value range from 0 to 3; 0 is the minimum (best) and 3 is the maximum (worst). The total score is computed by the sum of each subscale where the total ranges from the minimum 0 (best) to the maximum 12 (worst). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total Signs Score (TSS) | Baseline, Day 8, Day 15 | Change from baseline in lesion severity as measured by TSS at Day 8 and Day 15 Total Signs Score (TSS) of the lesion is the assessment of the severity of erythema, edema/papulation, excoriation, and lichenification. Each of these subscales is scored independently using the 4-point severity scale with a value range from 0 to 3; 0 is the minimum (best) and 3 is the maximum (worst). The total score is computed by the sum of each subscale where the total ranges from the minimum 0 (best) to the maximum 12 (worst). |
| Target Area Assessment (TAA) | Change from baseline in TAA at Day 8 and Day 15. | Change from baseline in TAA at Day 8 and Day 15 |
Countries
Canada
Outcome results
None listed